[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590807":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":49,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Laval University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"DEB",null,[12],"Device: DEB",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":10},"DEVICE","Use of DEB to treat coronary lesions",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Michele Jadin","CONTACT","418-6568711","michele.jadin@criucpq.ulaval.ca",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"IUCPQ","RECRUITING","Québec","Quebec","G1V4G5","Canada",{"type":33,"coordinates":34},"Point",[35,36],-71.21454,46.81228,{"lat":36,"lon":35},[39,41,44,47],{"name":20,"role":21,"phone":40,"phoneExt":10,"email":23},"418-656-8711",{"name":42,"role":43,"phone":10,"phoneExt":10,"email":10},"Olivier F. Bertrand, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":45,"role":46,"phone":10,"phoneExt":10,"email":10},"Tomas A. Cieza, MD","SUB_INVESTIGATOR",{"name":48,"role":46,"phone":10,"phoneExt":10,"email":10},"Andres R.A. Ruhl, MD",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Olivier F. Bertrand","MD, PhD","100590807",false,"NCT06972225","Restrospective Analysis of MACE in Patients Treated With Drug-elluting Balloons.","Follow-up of MACE in Patients Treated With Drug-eluting Balloons Between 2010 and 2025; a Retrospective Study With Prospective Follow-up From an Institutional Database: EASY-drug-eluting Balloons","EASY-DEB","Inclusion Criteria:\n\n* Adults (\\>=18 years of age)\n* Who underwent a coronary angioplasty with drug-eluting balloon between January 2010 and December 2025\n* Identified in the institutional procedure database\n\nExclusion Criteria:\n\n* Incomplete or non-available data on the post-procedural clinical follow-up\n* Procedures where other devices were used in combination with drug-eluting balloons.","ALL","18 Years",{"count":63,"type":64},1500,"ESTIMATED","OBSERVATIONAL","Retrospective analysis of data collected in an institutional database of coronary interventions with use of drug-eluting balloons, with a prospective follow-up for major adverse cardiovascular events and living status.",[68,69,70],"Coronary Arterial Disease (CAD)","Restenosis, Coronary","Bifurcation Coronary Disease","2026-04-15",{"date":73,"type":74},"2026-04-20","ACTUAL",{"date":76,"type":74},"2025-06-10",{"date":78,"type":64},"2036-03",{"name":51,"class":6},1]